相关实验视频

Updated: Sep 10, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

缺乏NF1的ER+乳腺癌对CDK4/6抑制剂有不同的敏感性

Ze-Yi Zheng^1,2, Anran Chen¹, Eric J Jaehnig¹

¹Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.

Science translational medicine

|August 27, 2025

概括

乳腺癌中神经纤维素 (NF1) 低导致对内分泌治疗的抵抗. 将CDK4/ 6抑制剂与标准治疗相结合,对NF1低瘤有希望,改善了临床前模型的结果.

科学领域:

癌症学
分子生物学
遗传学

背景情况:

神经纤维素 (NF1) 作为RAS GTPase激活蛋白和ER转录核心抑制剂.
在约20%的ER+/ HER2-早期乳腺癌中,NF1低的状态与内分泌疗法耐药性有关.
针对NF1低ER+/ HER2乳腺癌的向治疗是临床优先事项.

研究的目的:

调查NF1在ER+/ HER2-乳腺癌内分泌疗法耐药性的作用.
确定NF1低ER+/ HER2乳腺癌的潜在治疗策略.
阐明NF1对CDK4/6活性影响的分子机制.

主要方法:

对ER+/HER2乳腺癌的蛋白质基因分析.
涉及NF1删除的细胞系实验,以评估CDK4活性.
使用患者衍生异种移植和体外/体内研究的临床前建模.
对富尔韦斯特兰,CDK4/ 6抑制剂和芳香酶抑制剂的治疗反应的评估.

主要成果:

低NF1的瘤呈现出高林依赖激酶4/6 (CDK4/6) 的活性.
通过加强对CCND1和C-RAF激活的ER招募,NF1的删除会增加CDK4的活性.
低NF1的ER+癌细胞对富尔韦斯特兰特加上CDK4/ 6抑制剂的敏感性增加,导致细胞死亡和瘤回归.
在NF1低的ER+/ HER2瘤中,新辅助AI加上palbociclib的疗效大于单独的AI.

结论:

NF1 损失会同时激活 ER 和 RAS,增加 CDK4/ 6 的活性,并导致内分泌疗法抵抗.
低NF1的ER+乳腺癌容易受到CDK4/ 6的抑制.
需要临床级的NF1诊断来指导NF1低的乳腺癌患者的辅助治疗决定.

更多相关视频

Assessing Specificity of Anticancer Drugs In Vitro

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...